LivaNova PLC (NASDAQ: LIVN) announced new data showing its PolySync programming algorithm achieved a cumulative apnea-hypopnea index (AHI) response rate of 84.5% in patients with moderate to severe obstructive sleep apnea (OSA) treated with proximal hypoglossal nerve stimulation (pHGNS).

The findings were presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies, by lead author Alan R. Schwartz, M.D., adjunct professor of otorhinolaryngology at the University of Pennsylvania's Perelman School of Medicine.

The results build on LivaNova's OSPREY randomized controlled trial, which previously reported a 65% responder rate in the treatment arm after 12 months of pHGNS therapy using the company's aura6000 system. In the PolySync substudy, patients who did not meet responder criteria after one year of individual-contact stimulation underwent reprogramming using simultaneous-contact stimulation, which converted the majority of non-responders into responders and raised the cumulative response rate to 84.5%.

PolySync programming was reported to be well tolerated, with no serious treatment-emergent adverse events and no stimulation- or device-related adverse events recorded in the substudy.

"The ability to convert non-responders into responders through optimized programming represents an important advancement in treating Obstructive Sleep Apnea," Schwartz said.

LivaNova stated that PolySync will be available with its commercial pHGNS product. The company also said it plans to submit a premarket approval supplement application to the U.S. Food and Drug Administration for a next-generation OSA device in the second half of 2026. That device is being designed for MRI compatibility, remote configuration management, and a rechargeable battery with a stated lifespan of up to 15 years.

LivaNova received FDA premarket approval for the aura6000 system in March. The company is headquartered in London and employs approximately 3,300 people across more than 100 countries.